Cargando…
Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase
SIMPLE SUMMARY: Cyclin-dependent kinase (CDK) 4/6 inhibitors, in combination with endocrine therapies, are now the standard of care for patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Despite the effectiveness of CDK4/6 inhibitors,...
Autores principales: | Pandey, Kamal, Katuwal, Nar Bahadur, Park, Nahee, Hur, Jin, Cho, Young Bin, Kim, Seung Ki, Lee, Seung Ah, Kim, Isaac, Lee, Seung-Ryeol, Moon, Yong Wha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750394/ https://www.ncbi.nlm.nih.gov/pubmed/35008374 http://dx.doi.org/10.3390/cancers14010210 |
Ejemplares similares
-
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics
por: Pandey, Kamal, et al.
Publicado: (2021) -
Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020) -
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
por: Hur, Jin, et al.
Publicado: (2021) -
Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model
por: Park, Nahee, et al.
Publicado: (2020) -
Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer
por: Jeong, Yeong Gyu, et al.
Publicado: (2023)